Pipeline

The company’s focus is on highly morbid chronic disorders where medical innovation has been limited, if at all. Our initial target is a series of pathologies of the bladder affecting millions of people.

See more

Portfolio: Development status

Indication
Discovery
Preclinical
IND enabling
Phase 1
Phase 2
Phase 3
Neurogenic Detrusor Overactivity (NDO)
Product: EG110A
Indication
Discovery
Preclinical
IND enabling
Phase 1
Phase 2
Phase 3
Overactive bladder (OAB)
Product: EG110A
Indication
Discovery
Preclinical
IND enabling
Phase 1
Phase 2
Phase 3
Interstitial Cystitis (IC/PBS)
Product: EG110A
Indication
Discovery
Preclinical
IND enabling
Phase 1
Phase 2
Phase 3
Undisclosed neuromuscular disease
Product: EG132A
Indication
Discovery
Preclinical
IND enabling
Phase 1
Phase 2
Phase 3
Undisclosed sensory disease
Indication
Discovery
Preclinical
IND enabling
Phase 1
Phase 2
Phase 3
Undisclosed neurodegenerative disease